Latest filing published 12 May 2026 for Arcus Biosciences, Inc., €169k. Read the official filing
This profile gathers the share dealings of II Robert C. Goeltz in Arcus Biosciences, Inc., where the filings describe the role as finance chief. Between 16 December 2021 and 11 May 2026, the trades on record add up to 18 filings.
No open-market purchase appears, only 10 sales worth €854k. Outside the open market, there are 7 share grants. In 2026 alone, the filings show no purchases and 2 sales.
The newest entry dates from 12 May 2026: an open-market sale of €169k, in Arcus Biosciences, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
18 of 18 declarations